samedan logo
 
 
 
spacer
home > ebr > autumn 2009 > the biosimilars market
PUBLICATIONS
European Biopharmaceutical Review

The Biosimilars Market

 

Biosimilars, or ‘follow-on biologics’ as they are known in the US, provide access to affordable and effective medicines to patients around the world. Although the regulatory pathway put forward by the European Medicines Agency (EMEA) has facilitated the launch of a number of biosimilars, the market is still considered to be in a nascent stage. Estimates from IMS Health suggest that products worth $25 billion are expected to go off-patent by 2017, creating a significant opportunity for biosimilar players.

This article aims to set out the key challenges facing biosimilar market participants, in addition to various factors driving and restraining market growth. It also provides an overview of the competitive landscape of the current biosimilars industry and market trends.

THE ROLE OF BIOSIMILARS IN CONTROLLING PHARMACEUTICAL EXPENDITURE

One of the biggest problems facing developed economies around the world is the increase in per capita healthcare spending, which surpasses per capita income in several cases. As Figure 1 indicates, this trend is unsustainable in the long-run, and most governments have begun to take measures to ensure that spending growth falls in line with per capita income. Pharmaceutical expenditure, which is a critical component of healthcare budgets across the world, is being widely recognised as an area that needs to be controlled. This is precisely where generics and biosimilars have a crucial role to play. According to the European Generic medicines Association (EGA), generic medicines have made major contributions to affordable and accessible healthcare for over 20 years, saving the EU an estimated €20 billion annually. by 2017, creating a significant opportunity for biosimilar players.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sumanth Kambhammettu is a Programme Leader with the European Healthcare Practice of Frost & Sullivan. He focuses on analysing trends in the pharmaceutical and biotechnology markets. He has worked on various consulting projects and research reports in the areas of CNS, women’s health, cardiovascular therapeutics, generics and biosimilars, pricing and reimbursement issues, speciality pharma, stem cells, contract manufacturing organisations and several other issue-based topics. In addition, he is a regular contributor of articles on market related issues to leading industry journals. Prior to joining Frost & Sullivan, Sumanth had worked as a marketing executive with Baxter India’s renal division. Sumanth holds a B-Pharm (Hons) from the Birla Institute of Technology & Sciences (BITS), Pilani.
spacer
Sumanth Kambhammettu
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Language Weaver now available for ServiceNow customers

RWS, the world’s leading provider of technology-enabled language, content management, and intellectual property services, has released a new Language Weaver Connector for ServiceNow
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement